高尿酸血症市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、按藥物類型、按給藥途徑、按配銷通路、按地區和競爭進行細分，2020-2030 年

2024 年全球高尿酸血症市值為 45.6 億美元，預計到 2030 年將達到 67.1 億美元，預測期內的年複合成長率(CAGR) 為 6.63%。該市場代表了醫療保健行業一個充滿活力且不斷發展的領域，主要關注高尿酸血症（一種以血液中尿酸水平升高為特徵的疾病）的診斷、治療和管理。

高尿酸血症通常與痛風（一種發炎性關節炎）有關，也與腎結石和心血管疾病等其他疾病有關。近年來，受多種關鍵促進因素的推動，市場經歷了顯著成長。

關鍵市場促進因素

高尿酸血症盛行率上升

主要市場挑戰

缺乏常規篩檢

主要市場趨勢

專注於研發（R&D）

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：全球高尿酸血症市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按類型（小學、中學）
  • 依藥物類型（黃嘌呤氧化酶抑制劑、非類固醇抗發炎藥、皮質類固醇等）
  • 依給藥途徑（口服、注射）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按類型
  • 依藥物類型
  • 依給藥途徑
  • 按配銷通路
  • 按地區

第5章：亞太高尿酸血症市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按類型
  • 依藥物類型
  • 依給藥途徑
  • 按配銷通路
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第6章：歐洲高尿酸血症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第7章：北美高尿酸血症市場展望

• 市場規模和預測
• 市場佔有率和預測
  • 類型
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第8章：南美洲高尿酸血症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第9章：中東和非洲高尿酸血症市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：市場動態

• 驅動程式
• 挑戰

第 11 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 12 章：全球高尿酸血症市場：SWOT 分析

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Arthrosi Therapeutics, Inc
• Dr. Reddy's Laboratories Ltd.
• Urica Therapeutics, Inc
• Zydus Lifesciences
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Hikma Pharmaceuticals Plc
• Mylan NV
• AstraZeneca Plc
• Sun Pharmaceutical Industries Ltd

第 15 章：策略建議

第16章調查會社について,免責事項

Global Hyperuricemia Market was valued at USD 4.56 billion in 2024 and is projected to reach USD 6.71 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.63% during the forecast period. This market represents a dynamic and evolving segment of the healthcare industry, centered on the diagnosis, treatment, and management of hyperuricemia-an ailment marked by elevated uric acid levels in the bloodstream.

Hyperuricemia is commonly associated with gout, a form of inflammatory arthritis, and is also linked to other medical conditions such as kidney stones and cardiovascular disease. The market has experienced notable growth in recent years, propelled by several key drivers.

Key Market Drivers

Rising Prevalence of Hyperuricemia

The increasing global incidence of hyperuricemia serves as a primary growth catalyst for this market. In the United States alone, approximately 38 million people-over 11% of the population-are affected by this condition. Globally, this trend is being fueled by lifestyle factors such as poor dietary habits, physical inactivity, and the growing prevalence of obesity. Notably, in 2022, over one billion individuals worldwide were classified as obese, a condition strongly correlated with elevated uric acid levels.

This rising prevalence has led to heightened demand for both diagnostic tools and therapeutic solutions. Greater public awareness regarding the health risks posed by hyperuricemia has led to increased medical consultations, encouraging early diagnosis and proactive disease management. Furthermore, the aging global population is another significant contributor, as the risk of hyperuricemia rises with age due to diminished renal function. By 2050, individuals aged 60 and above are expected to constitute 22% of the global population, up from 12% in 2015-further intensifying the need for effective management and treatment strategies.

Key Market Challenges

Lack of Routine Screening

One of the critical challenges facing the hyperuricemia market is the limited implementation of routine screening protocols. Hyperuricemia often progresses silently, with few or no symptoms until it leads to more serious complications such as gout, kidney stones, or cardiovascular disorders. Without routine screening, many individuals remain undiagnosed until the condition reaches an advanced stage, resulting in delayed treatment and elevated healthcare costs.

Routine screening not only enables early detection but also provides an opportunity for patient education and preventive intervention through lifestyle modifications-such as improved diet, weight management, and physical activity. Proactive screening is thus a cost-effective strategy to mitigate long-term health complications and reduce the economic burden on healthcare systems.

Key Market Trends

Focus on Research and Development (R&D)

Innovation through research and development has emerged as a central theme in the evolution of the global hyperuricemia market. With strong correlations between hyperuricemia and other debilitating conditions like gout and cardiovascular disease, the need for advanced therapeutic solutions has intensified.

Pharmaceutical companies and academic research institutions are actively pursuing novel treatment approaches, including gene therapy aimed at modifying the genetic pathways that regulate uric acid metabolism. Such innovations could lead to more effective and precisely targeted interventions.

Another emerging trend is the integration of precision medicine into hyperuricemia management. By leveraging patients' genetic, biochemical, and lifestyle data, healthcare providers can deliver highly customized treatment plans that enhance efficacy and reduce adverse effects-ultimately improving patient outcomes.

Ongoing research is also deepening the understanding of the biological mechanisms underlying hyperuricemia and its comorbidities. These insights are aiding in the development of more sophisticated diagnostic tools and next-generation therapeutics, thereby driving sustained market growth.

Key Market Players

• Arthrosi Therapeutics, Inc
• Dr. Reddy's Laboratories Ltd.
• Urica Therapeutics, Inc
• Zydus Lifesciences
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Hikma Pharmaceuticals Plc
• Mylan N.V.
• AstraZeneca Plc
• Sun Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Hyperuricemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hyperuricemia Market, By Type:

• Primary
• Secondary

Hyperuricemia Market, By Drug Type:

• Xanthine Oxidase Inhibitors
• Nonsteroidal Anti-Inflammatory Drugs
• Corticosteroids
• Others

Hyperuricemia Market, By Route of Administration:

• Oral
• Injectable

Hyperuricemia Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hyperuricemia Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hyperuricemia Market.

Available Customizations:

Global Hyperuricemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Hyperuricemia Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Primary, Secondary)
  • 4.2.2. By Drug Type (Xanthine Oxidase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Others)
  • 4.2.3. By Route of Administration (Oral, Injectable)
  • 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Drug Type
  • 4.3.3. By Route of Administration
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Asia Pacific Hyperuricemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Drug Type
  • 5.2.3. By Route of Administration
  • 5.2.4. By Distribution Channel
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Hyperuricemia Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Drug Type
      • 5.3.1.2.3. By Route of Administration
      • 5.3.1.2.4. By Distribution Channel
  • 5.3.2. India Hyperuricemia Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Drug Type
      • 5.3.2.2.3. By Route of Administration
      • 5.3.2.2.4. By Distribution Channel
  • 5.3.3. Australia Hyperuricemia Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Drug Type
      • 5.3.3.2.3. By Route of Administration
      • 5.3.3.2.4. By Distribution Channel
  • 5.3.4. Japan Hyperuricemia Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Drug Type
      • 5.3.4.2.3. By Route of Administration
      • 5.3.4.2.4. By Distribution Channel
  • 5.3.5. South Korea Hyperuricemia Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Drug Type
      • 5.3.5.2.3. By Route of Administration
      • 5.3.5.2.4. By Distribution Channel

6. Europe Hyperuricemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Hyperuricemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Germany Hyperuricemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Spain Hyperuricemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Italy Hyperuricemia Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Drug Type
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. United Kingdom Hyperuricemia Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Drug Type
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By Distribution Channel

7. North America Hyperuricemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Hyperuricemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Mexico Hyperuricemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Canada Hyperuricemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel

8. South America Hyperuricemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Hyperuricemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Argentina Hyperuricemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Colombia Hyperuricemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Hyperuricemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Hyperuricemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Saudi Arabia Hyperuricemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. UAE Hyperuricemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Hyperuricemia Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Arthrosi Therapeutics, Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Dr. Reddy's Laboratories Ltd.
• 14.3. Urica Therapeutics, Inc
• 14.4. Zydus Lifesciences
• 14.5. Takeda Pharmaceutical Company Limited
• 14.6. Novartis AG
• 14.7. Hikma Pharmaceuticals Plc
• 14.8. Mylan N.V.
• 14.9. AstraZeneca Plc
• 14.10.Sun Pharmaceutical Industries Ltd

15. Strategic Recommendations

16. About Us & Disclaimer